GlobalData on MSN

Devonian’s Phase II/III Thykamine paediatric study secures Health Canada approval

In total, around 306 patients are expected to be enrolled in the trial.
Business Wire

Devonian Health Group Reports Third Quarter 2024 Financial Results and Business Update and Announces Engagement of Investor Relations Firm

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its third quarter ended on April 30, 2024.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Pat…

Detailed price information for Devonian Health Group Inc (GSD-X) from The Globe and Mail including charting and trades.
Business Wire

Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent

QUEBEC CITY-- (BUSINESS WIRE)--Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to ...
Yahoo Finance

Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member

"Our year-end results reflect a company that is financially disciplined, debt-free, and strategically positioned for the next phase of value creation. With this strong foundation, we are intensifying ...
Yahoo Finance

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

QUEBEC, Feb. 17, 2026 /CNW/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed in two ...